BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.

A control room that thinks it knows what happens next Walk the mezzanine above a modern biologics suite in Singapore, Songdo or Hyderabad and the change i...

July 10, 2026 | Analysis

APAC's Peptide-Capacity Gamble

For most of pharmaceutical history, the hard part was finding a molecule that worked. The GLP-1 class inverted that logic. The science arrived first &mdash...

July 09, 2026 | Analysis

After the Rush: APAC's mRNA and Vaccine Capacity Hangover

In June 2022, South Korea had something it had wanted for two years: a COVID-19 vaccine of its own. SKYCovione, developed by SK bioscience with the U...

July 08, 2026 | Analysis

The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?

In Songdo and Bengaluru, the numbers finally look like the ones the region was promised a decade ago. Celltrion closed 2025 with revenue above ₩4 trillio...

July 07, 2026 | Analysis

The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?

The requirement: a chain that cannot break Key figures −150°C or colder — the temperature floor for most cell and gene therapies; som...

July 06, 2026 | Analysis

Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck

THE GATE The choke point nobody puts on the slide Somewhere in the region this quarter, a cell-and-gene developer has everything the pitch deck promised....

July 03, 2026 | Analysis

Can APAC Build Radioligand Therapy Before the Atoms Decay?

Every dose of radioligand therapy is a countdown. The moment a batch of lutetium-177 leaves the reactor, it begins to fade — roughly half its therape...

July 02, 2026 | Analysis

Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?

A new medicine arrives at a regulator's desk with two kinds of proof attached. The first is the familiar kind: a randomised controlled trial, blinded, cont...

June 30, 2026 | Analysis

Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next

For most of the last decade, the strategic case for running Asia-Pacific clinical trials could be summarised in a single word: China. A vast, treatment-n...

June 29, 2026 | Analysis

The Frontier That Won’t Quite Arrive

Ask the region’s clinical-operations leaders whether decentralised and hybrid trials are the future, and the answer is almost unanimous. Surveys keep...

June 26, 2026 | Analysis

Vendor to Co-Innovator — or Bring It In-House? The CDMO Relationship Rewires

For two decades the contract development and manufacturing organisation occupied a comfortable, clearly understood place in the biopharma value chain. The ...

June 25, 2026 | Analysis

Security at What Cost? APAC and the Great Supply-Chain Reordering

For the better part of two decades, the global pharmaceutical supply chain ran on a simple, unsentimental bargain: make the chemistry where it is cheapest,...

June 24, 2026 | Analysis

After the Drug Substance, the Real Squeeze: APAC's Aseptic Fill-Finish Gap

For most of the last decade, the anxiety in Asia-Pacific biomanufacturing pointed upstream. The conversation was about bioreactor volume — how many t...

June 22, 2026 | Analysis

Billions on Bioconjugation: Is APAC Building the Right ADC Capacity — or Too Much?

In Songdo, on the reclaimed waterfront west of Seoul, a 202,000-square-metre construction site is becoming the most expensive single statement Kore...

June 19, 2026 | Analysis

Stay Connected